DIMA

DIMA:

Leading product AF-29 is in late preclinical stage of development. Superior IL-1 signaling inhibition efficacy and prolonged PK were confirmed in rodent models. IND application is expected in Q2/2026. 

AF-29
  • Novel design of bispecific antibody enables blocking IL-1 signaling on inflammation relevant cells
  • Superior potency compared with mAb competitorsacross multiple rodent models, including ~100-fold higher activity than IL-1β mAb Canakinumab
  • Exhibited favorable pharmacokinetic and toxicology profiles in both rodents and NHPs
  • No observable toxicity in NHP up to 150mg/kg dose level
  • Optimized half-lives of the two binding motifs to balance efficacy and side effects, supporting Q4W dosing in human
  • Favorable physiochemical and pharmacological properties, enabling subcutaneous administration
  • Potential therapeutic application across multiple inflammatory and autoimmune diseases, either as monotherapy or in combination with existing treatments
  • Completed process development to support manufacture of toxicity study and clinical trial material
Scroll to Top